Pacira BioSciences Newsroom

VectorY Strengthens Leadership Team With Appointment of Jim Scibetta as New CEO

BusinesswireDec 16 07:00 ET

Express News | Doma Perpetual: Urges Pacira to Immediately Commence Stock Tender Offer for 10 Mln Shares Using Its Substantial Cash on Hand

ReutersDec 11 08:06 ET

Express News | Doma Perpetual: Believes Pacira Biosciences' Stock Is "Grossly Undervalued"

ReutersDec 11 08:06 ET

Express News | Doma Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira Biosciences, Inc.

ReutersDec 11 08:05 ET

DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.

PR NewswireDec 11 08:05 ET

Pacira BioSciences (NASDAQ:PCRX) Shareholders Are up 7.2% This Past Week, but Still in the Red Over the Last Three Years

Simply Wall StDec 10 14:28 ET

Press Release: Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Dow JonesDec 6 08:00 ET

Express News | Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 6 08:00 ET

H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $39

Moomoo NewsDec 5 11:35 ET · Ratings

PCRX Receives New Patent for Lead Pain Drug Exparel in the US

Zacks Dec 4 11:30 ET

Decoding 6 Analyst Evaluations For Pacira BioSciences

BenzingaDec 4 07:00 ET

Express News | HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $39 Price Target

BenzingaDec 4 06:28 ET

Express News | Pacira Biosciences Inc: Awarded New U.S. Patent Covering Exparel Composition; Provides Protection Into 2044

ReutersDec 3 07:32 ET

US Manufacturing Index Rises To 43, Highest Since 2020

Business TodayNov 16 02:13 ET

Pacira BioSciences Reports Sustained Pain Relief in Osteoarthritis With Gene Therapy Candidate PCRX-201 in Upcoming ACR Presentation

Quiver QuantitativeNov 14 10:47 ET

Express News | Pacira Biosciences Inc - Phase 1 Trial Shows Safety and Efficacy of Pcrx-201

ReutersNov 14 10:05 ET

Express News | Pacira Biosciences Inc - No Serious Treatment-Emergent Adverse Events Reported

ReutersNov 14 10:05 ET

Express News | Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of Pcrx-201 for Moderate to Severe Osteoarthritis of the Knee

ReutersNov 14 10:05 ET

Pacira BioSciences Insider Lowered Holding By 85% During Last Year

Simply Wall StNov 14 05:30 ET

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Pacira BioSciencesNov 14 00:00 ET